Targeted Protein Degradation

Georg Winter is a Principal Investigator at CeMM, the Research Center for Molecular Medicine of the Austrian Academy of Sciences, and member of our FWF-funded SFB consortium. Prior to this, he was a postdoctoral researcher at the Dana Farber Cancer Institute at Harvard Medical School in the USA. Tailor-made small molecules that bind to cancer-causing proteins and thus render tumor cells harmless – this is Georg Winter’s area of expertise, in which he is one of the world’s leading experts. Winter is the founder of several companies; his research at CeMM has resulted in Proxygen, one of the most successful start-up companies in Vienna. Georg Winter was the only scientist conducting research in Austria to win the Cancer Grand Challenge as part of a consortium in spring 2024.

Georg Winter’s work in targeted protein degradation is not only advancing fundamental research but also paving the way for practical applications. The consortium of our Special Research Program congratulates him on his appointment as Life Science Director of AITHYRA, OeAW’s newly founded institute. It’s a privilege to have him as group leader within our SFB research consortium.

Georg Winter: “I am very much looking forward to my new role and working with Michael Bronstein [AI Scientific Director of AITHYRA]. Our common goal is to accelerate scientific knowledge and answer fundamental questions in the life sciences by integrating biomedical research and AI. In this way, we want to develop completely new treatment methods for cancer and other life-threatening diseases.”

Read this News at AITHYRA.

Read this News at the Vienna BioCenter

Read this News at CeMM

Read about Georg’s project in our SFB Special Research Program.